This is a past event. Registration is closed. View other Viva Biotech Holdings events.
Cheney Mao
Chairman & CEO of Viva BiotechPh.D. in Biochemistry from Cornell University
Post-doc research from Duke Medical Center
Former Director of the Department of Structural Biology of the Parker Hughes Institute
David Xu
CBO at Viva BiotechPh.D. from University of California, Los Angeles
Postdoctoral research at the Scripps Research Institute
M.B.A from Wharton School of Business, University of Pennsylvania
Worked in Purdue, Sandoz, and Novartis
Cooke Mike
Co-Founder&CEO of AmacaTheraMike Cooke joined Molly's laboratory in 2008 as a post-doctoral fellow to work on stem cell transplantation for recovery following stroke. This resulted in a co-first author publication in Stem Cell Reports demonstrating cells combined with HAMC could restore stroke injury in a model of stroke.
Together with Molly, Mike developed the first product for AmacaThera, a sustained analgesic for post-operative pain. This product is nearing completion of pre-clinical studies and IND enabling studies will commence in 2018. Mike pitched to both UTEST and OBIO, securing dilutive and non-dilutive seed investment for AmacaThera.
Gang Liu
Founder&CSO of XLementUniversity of California. Berkeley/Ph.D. in Bioengineering major
University of California, San Francisco/Ph.D. in Cell and Molecular Medicine major
University of Illinois at Urbana-Champaign/Tenured professor
Deborah Kurrasch
Co-Founder&CEO of Path TherapeauticsDr. Kurrasch is a basic science researcher and associate professor at the University of Calgary who has expertise in animal models of CNS disorders and pharmacology.
Wang Shen
Founder&CEO of VivaVision BiotechPh.D., University of Pittsburgh
Experience in Abbott, Kanion, Amgen, Sunesis
Richard Austin
CEO of ReglageneRichard leads Reglagene’s business operations and fund-raising. Before founding Reglagene, he built a 23- year career in pharmaceutical R&D at GSK and Sanofi in which he served as a medicinal chemist, drug discovery project leader, analytical chemistry services manager, and research operations manager. Recognizing an affinity for the business side of the pharmaceutical industry, in 2010 Richard earned an MBA in Pharmaceutical Management from Drexel University in Philadelphia Pennsylvania. He soon transitioned into a managerial role at Sanofi’s Tucson, Arizona Research Center with responsibilities for operational and capital spending, procurement, equipment maintenance, and other business areas. Richard is a member of Tucson’s Desert Angels, one of the most active angel investment groups in the United States. While serving as a Commercialization Partner for the University of Arizona, Richard was introduced to quadruplex gene expression control. Seeing the potential in the technology, he co-founded Reglagene in November 2016. Richard earned a PhD in Organic Chemistry from the University of Texas in 1991 and completed post-doctoral studies in bioorganic chemistry at the University of California Berkeley in 1993.